• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[外泌体介导急性肺损伤免疫调节的研究进展]

[Research progress on exosome-mediated immune regulation of acute lung injury].

作者信息

Li Jiaqi, Liu Mingzhuo, Hu Yong, Guo Guanghua

机构信息

Department of Burn, the First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China. Corresponding author: Guo Guanghua, Email:

出版信息

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021 Jan;33(1):118-121. doi: 10.3760/cma.j.cn121430-20200408-00262.

DOI:10.3760/cma.j.cn121430-20200408-00262
PMID:33565415
Abstract

Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is a respiratory disorder with high morbidity and mortality caused by various causes. Exosomes can mediate cell communication through paracrine pathways, transfer proteins, lipids, nucleic acids, etc., and interfere with the biological functions of recipient cells. Various cell-derived exosomes have been reported to play an immunomodulatory role in the ALI/ARDS inflammatory model. This article reviews the mechanism of exosomes involved in immune regulation of ALI/ARDS and possible therapeutic approaches.

摘要

急性肺损伤/急性呼吸窘迫综合征(ALI/ARDS)是一种由多种原因引起的、具有高发病率和死亡率的呼吸系统疾病。外泌体可以通过旁分泌途径介导细胞间通讯,转运蛋白质、脂质、核酸等,并干扰受体细胞的生物学功能。据报道,各种细胞来源的外泌体在ALI/ARDS炎症模型中发挥免疫调节作用。本文综述了外泌体参与ALI/ARDS免疫调节的机制及可能的治疗方法。

相似文献

1
[Research progress on exosome-mediated immune regulation of acute lung injury].[外泌体介导急性肺损伤免疫调节的研究进展]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021 Jan;33(1):118-121. doi: 10.3760/cma.j.cn121430-20200408-00262.
2
Advances in the use of exosomes for the treatment of ALI/ARDS.外泌体在治疗 ALI/ARDS 中的应用进展。
Front Immunol. 2022 Aug 9;13:971189. doi: 10.3389/fimmu.2022.971189. eCollection 2022.
3
Stem cell derived exosomes-based therapy for acute lung injury and acute respiratory distress syndrome: A novel therapeutic strategy.基于干细胞衍生的外泌体的急性肺损伤和急性呼吸窘迫综合征治疗:一种新的治疗策略。
Life Sci. 2020 Aug 1;254:117766. doi: 10.1016/j.lfs.2020.117766. Epub 2020 May 11.
4
A Bibliometric Analysis of Mesenchymal Stem Cell-Derived Exosomes in Acute Lung Injury/Acute Respiratory Distress Syndrome from 2013 to 2022.2013 年至 2022 年间间充质干细胞衍生的外泌体在急性肺损伤/急性呼吸窘迫综合征中的文献计量学分析
Drug Des Devel Ther. 2023 Jul 25;17:2165-2181. doi: 10.2147/DDDT.S415659. eCollection 2023.
5
Delivery systems of therapeutic nucleic acids for the treatment of acute lung injury/acute respiratory distress syndrome.治疗性核酸递药系统治疗急性肺损伤/急性呼吸窘迫综合征。
J Control Release. 2023 Aug;360:1-14. doi: 10.1016/j.jconrel.2023.06.018. Epub 2023 Jun 19.
6
Extracellular vesicles in acute respiratory distress syndrome: Recent developments from bench to bedside.急性呼吸窘迫综合征中的细胞外囊泡:从实验台到临床的最新进展
Int Immunopharmacol. 2021 Nov;100:108118. doi: 10.1016/j.intimp.2021.108118. Epub 2021 Sep 1.
7
[Serpins as important protective factors in the pathogenesis of acute lung injury/acute respiratory distress syndrome].[丝氨酸蛋白酶抑制剂作为急性肺损伤/急性呼吸窘迫综合征发病机制中的重要保护因素]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021 Mar;33(3):368-372. doi: 10.3760/cma.j.cn121430-20200922-00644.
8
Progress in preclinical studies of macrophage autophagy in the regulation of ALI/ARDS.巨噬细胞自噬在调控 ALI/ARDS 中的基础研究进展。
Front Immunol. 2022 Aug 18;13:922702. doi: 10.3389/fimmu.2022.922702. eCollection 2022.
9
Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes.使用间充质干细胞衍生的外泌体治疗 COVID-19 诱导的急性呼吸窘迫综合征和肺损伤的假设。
Med Hypotheses. 2020 Nov;144:109865. doi: 10.1016/j.mehy.2020.109865. Epub 2020 May 22.
10
Intracellularly Synthesized Artificial Exosome Treats Acute Lung Injury.细胞内合成的人工外泌体治疗急性肺损伤。
ACS Nano. 2024 Aug 13;18(32):21009-21023. doi: 10.1021/acsnano.4c01900. Epub 2024 Aug 1.